Old hormone, new hope: estradiol trial targets tough breast cancers

NCT ID NCT05716516

Recruiting now Disease control Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests estradiol, a form of estrogen, in postmenopausal women with advanced ER+ breast cancer that has stopped responding to other hormone therapies. The goal is to see if patients with a specific genetic change (ESR1 mutation) benefit more than those without it. The trial enrolls 36 participants and measures tumor shrinkage and disease control at 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Estradiol (a form of estrogen hormone)
What this could lead to: If successful, this could show that estradiol therapy benefits certain patients with advanced breast cancer who have specific genetic changes.
What could go wrong: This is a small early-phase trial with only 36 participants, so results may not apply broadly. Estradiol can cause side effects like blood clots or hormone-related symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER+ METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm estrogen-receptor positive breast cancer Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Dartmouth-Hitchcock Medical Center
RECRUITING

Lebanon, New Hampshire, 03756, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.